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BACKGROUND AND PURPOSE: The EFFECTS (Efficacy of Fluoxetine—a Randomised Controlled Trial in Stroke) recently reported 
that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression 
and increased fractures and hyponatremia at 6 months. The purpose of this predefined secondary analysis was to identify if 
any effects of fluoxetine were maintained or delayed over 12 months.
METHODS: EFFECTS was an investigator-led, randomized, placebo-controlled, double-blind, parallel group trial in Sweden that 
enrolled adult patients with stroke. Patients were randomized to 20 mg oral fluoxetine or matching placebo for 6 months 
and followed for another 6 months. The primary outcome was functional outcome (modified Rankin Scale), at 6 months. 
Predefined secondary outcomes for these analyses included the modified Rankin Scale, health status, quality of life, fatigue, 
mood, and depression at 12 months.
RESULTS: One thousand five hundred patients were recruited from 35 centers in Sweden between 2014 and 2019; 750 
were allocated fluoxetine and 750 placebo. At 12 months, modified Rankin Scale data were available in 715 (95%) patients 
allocated fluoxetine and 712 (95%) placebo. The distribution of modified Rankin Scale categories was similar in the 2 groups 
(adjusted common odds ratio, 0.92 [95% CI, 0.76–1.10]). Patients allocated fluoxetine scored worse on memory with a 
median value of 89 (interquartile range, 75–100) versus 93 (interquartile range, 82–100); P=0.0021 and communication 
93 (interquartile range, 82–100) versus 96 (interquartile range, 86–100); P=0.024 domains of the Stroke Impact Scale 
compared with placebo. There were no other differences in secondary outcomes.
CONCLUSIONS: Fluoxetine after acute stroke had no effect on functional outcome at 12 months. Patients allocated fluoxetine scored 
worse on memory and communication on the Stroke Impact Scale compared with placebo, but this is likely to be due to chance.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02683213.
GRAPHIC ABSTRACT: An online graphic abstract is available for this article.
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 ◼ serotonin uptake inhibitors ◼ stroke
In 2011, the FLAME trial (Fluoxetine for Motor Recov-ery After Acute Ischemic Stroke) reported that fluox-etine enhanced motor recovery after acute ischemic 
stroke.1 A Cochrane systematic review of 4059 patients 
included in 52 randomized controlled trials of SSRIs 
(selective serotonin reuptake inhibitors) for stroke 
recovery concluded that SSRIs could reduce disabil-
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heterogeneity of the trials, more data were needed.2 In 
2020, the EFFECTS (Efficacy of Fluoxetine—a Ran-
domised Controlled Trial in Stroke) authors reported that 
20 mg of fluoxetine once daily for 6 months after acute 
stroke did not improve functional outcome at 6 months 
compared with placebo, although the occurrence of 
depression was reduced and fractures and hyponatre-
mia increased.3 EFFECTS included 1500 stroke patients 
from Sweden, and the results were similar to those of 2 
other large randomized controlled trials with comparable 
design.4,5
As specified in the protocol6,7 and statistical analy-
sis plan,8 we followed-up participants to 12 months, to 
examine whether any effects of fluoxetine identified at 6 
months were sustained or delayed.
METHODS
The anonymized data that support the findings of this trial are 
available to other researchers from the corresponding author 
(Dr Lundström) upon reasonable request following receipt of a 
written application and proposal for use of the data, approval by 
the EFFECTS trial Steering Committee, and establishment of a 
data sharing agreement.
The design, methods, and primary results of the EFFECTS 
trial have been published.3,6–8 Briefly, EFFECTS was a random-
ized, double-blind, placebo-controlled clinical trial conducted 
in 35 hospital stroke units in Sweden. The trial was approved 
by a central medical ethics committee in Stockholm (refer-
ence 2013/1265-31/2) and by the Swedish Medical Agency 
(reference 5.1-2014-43006); all patients provided written 
informed consent. EFFECTS was registered in the EU Clinical 
Trials Register and ClinicalTrials.gov. We have followed the 
CONSORT statement (Consolidated Standards of Reporting 
Trials).9
Eligible patients were adults (aged ≥18 years) with a clini-
cal diagnosis of acute stroke within the previous 2 to 15 days, 
brain imaging consistent with ischemic or hemorrhagic stroke, 
and a persisting neurological deficit at the time of randomiza-
tion. Patients were excluded if they were depressed or taking 
antidepressants; had a contraindication to fluoxetine; were 
unlikely to be available for follow-up during the subsequent 12 
months; had another life-threatening illness that would make 
12-month survival unlikely; were enrolled in another clinical trial 
of an investigational medicinal product or device; and women 
were excluded if pregnant, breast-feeding, or of child-bearing 
age and not using contraception. Baseline characteristics and 
outcome at 6 months are available in Tables I through III in the 
Data Supplement.
Randomization was via a secure, centralized, web-based 
system which used a minimization algorithm3 and assigned 
patients to fluoxetine or placebo in a 1:1 ratio. Placebo cap-
sules were visually identical to the fluoxetine capsules even 
when broken open. Fluoxetine 20 mg capsules or matching 
placebo capsules were administered orally once daily for 6 
months.
Patients were followed-up at 6 and 12 months by postal 
questionnaire or telephone by one research nurse (N. 
Greilert Norin) in the trial coordinating center at Danderyd 
Hospital. If the patient was unable to complete the question-
naire, assistance was sought from their next of kin or carer. 
In this article, we report the following predefined secondary 
outcomes at 12 months:
1. Functional status, measured with the modified Rankin 
Scale (mRS).10 We used the simple mRS question-
naire11–13 to derive the mRS score.
2. Health status using the Stroke Impact Scale version 
3.0.14 The Stroke Impact Scale is a 59-item self-reported 
questionnaire that includes 8 domains: arm, hand, leg, 
and foot strength; hand function; mobility; communica-
tion and understanding; memory and thinking; mood 
and emotions; daily activities; and participation in work, 
leisure, and social activities. Four of the subscales 
(strength, hand function, daily activities, and mobility) 
can be combined into a composite physical domain. 
Scores for each domain range from 0 to 100, and higher 
scores indicate better health. The Stroke Impact Scale 
also contains a question to assess the patient’s global 
experience of recovery. The patient is asked to score 
their recovery on a visual analog scale ranging from 0 
to 100, with 0 meaning no recovery and 100 meaning 
full recovery.
3. Depression, defined as taking an antidepressant medi-
cation (Anatomic Therapeutic Chemical code beginning 
with N06A) at 12 months.
4. Mood, using the Mental Health Inventory 5 scale.15 The 
Mental Health Inventory 5 is a subscale of the 36-Item 
Short Form Health Survey16 containing 5 questions, 
each with 6 possible answers, with a score of 1 to 6; 
possible sum of scores ranges from 5 to 30. The total 
score is transformed into a value between 0 and 100, 
where 100 represents optimal mental health. A value 
below 60 has been suggested as moderate-to-poor 
mental health.17
5. Fatigue, using the vitality subscale18 of the 36-Item Short 
Form Health Survey. Four questions, each with 5 answers 
scored from 1 to 5 (sum ranges from 4–20). The sum 
score is transformed to a value between 0 and 100. 
Scores below 50 indicate fatigue.19
6. Health-related quality of life, measured with the 
EQ-5D-5L.20 EQ-5D-5 L includes 5 dimensions: mobil-
ity; personal care; usual activities; pain/discomfort; and 
Nonstandard Abbreviations and Acronyms
AFFINITY  Assessment of Fluoxetine in Stroke 
Recovery Trial
EFFECTS  Efficacy of Fluoxetine—a Randomised 
Controlled Trial in Stroke
FLAME  Fluoxetine for Motor Recovery After 
Acute Ischemic Stroke Trial
FOCUS  Fluoxetine or Control Under Supervision 
trial
mRS modified Rankin Scale
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anxiety/depression. We calculated an EQ-5D index—
where 1 indicates the best health imaginable, and 0 
indicates the worst health imaginable—using the UK 
cross-walk value set, since it is the most commonly used.21
The participant, care provider, investigator, and outcomes 
assessor remained masked to the allocated trial treatment until 
the 12 month assessment.
Except death, we did not collect any adverse event or safety 
outcome data between 6 and 12 months. Long-term follow-up 
is planned to at least 3 years using central registries.
Statistical Analysis
We published the statistical analysis plan before recruitment 
was completed and without awareness of any unmasked data.8
The primary outcome for this report, the mRS scores at 
12 months, were analyzed using ordinal logistic regression 
before and after adjusting for the baseline factors included 
in the minimization algorithm.3 We used the following co-vari-
ables in the algorithm: days between stroke and randomiza-
tion; probability of being alive and independent at 6 months; 
motor deficit; and aphasia. We presented the results as an 
adjusted and a nonadjusted common odds ratio where a num-
ber below 1.0 indicates that placebo is better than fluoxetine, 
with a 95% CI.
The secondary outcomes were compared (unadjusted) 
using Mann-Whitney U test. For continuous secondary out-
comes, the mean or median in each group was calculated with 
SD or interquartile range (IQR), depending on the distribution. 
The probability that outcomes in the fluoxetine group were sig-
nificantly different from the placebo group were calculated as 
P values (2-sided).
All analyses were by intention-to-treat, and were carried out 
in SAS for Windows, Software 9.4, SAS Institute Inc, Cary, NC.
RESULTS
EFFECTS recruitment started 20 October, 2014 and 
ended 28 June, 2019; 750 were assigned to fluoxetine 
and 750 to placebo. Last 12 months follow-up was 8 
July, 2020. Baseline characteristics were well balanced, 
87.4% had ischemic stroke, 12.3% had intracerebral 
hemorrhage, 0.2% had nonstroke. The mean age was 71 
years (SD, 11), 38.3% were women, 96.3% were pre-
viously independent, and the median National Institutes 
of Health Stroke Scale score was 3.3 For both groups, 
the median duration of treatment was 180 days (IQR, 
Figure. CONSORT (Consolidated Standards of Reporting Trials) flow diagram.
*Two patients (one in each group) withdrew their consent regarding face-to-face follow-up, however, they both agreed to answer the questionnaire 
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180–180). Most patients (1338/1500, 89%) took the 
trial medication for at least 150 days.3
At 12 months, mRS data were available for 715 
(95%) patients in the fluoxetine group and 712 (95%) 
patients in the placebo group (Figure 1). No patients 
withdrew consent for follow-up between 6 and 12 
months; 4.1% (62/1500) were lost to follow-up at 12 
months, and 4.5% (68/1500) died within 12 months 
(Table IV in the Data Supplement).
Table 1 shows the mRS10 scores 12 months after 
randomization, that is, 6 months after cessation of trial 
medication. There was no difference in the distribution 
across mRS categories in the fluoxetine and placebo 
groups (adjusted common odds ratio, 0.92 [95% CI, 
0.76–1.10]). The unadjusted analysis produced similar 
results (common odds ratio, 0.96 [95% CI, 0.80–1.15]; 
Table 1).
Table 2 shows the secondary outcomes in the fluox-
etine and placebo groups. Patients randomized to fluox-
etine had significantly worse values on the memory 
(median value of 89 [IQR, 75–100] versus 93 [IQR, 
82–100]; P=0.0021] and communication (93 [IQR, 
82–100] versus 96 [IQR, 86–100]; P=0.024) domains 
of the Stroke Impact Scale v3 compared with placebo. 
There were no other differences on the secondary out-
comes (Table 2).
Six months after randomization, 5.8% (87/1500) of 
the patients reported that they were taking an open-label 
antidepressant; 4.8% (36/750) had been randomized to 
fluoxetine, and 6.8% (51/750) to placebo.4
At 12 months follow-up, 8.8% of the survivors from 6 
months (129/1453) were taking an open-label antide-
pressant; 9.0% (65/725) randomized to fluoxetine, and 
8.8% (64/728) to placebo (diff, 0.2% [95% CI, −3.1 to 
3.8]; Tables V and VI in the Data Supplement). Of patients 
on an antidepressant at 6 months, 60% (51/87) patients 
continued to take antidepressant at 12 months follow-
up; 41% (21/36) randomized to fluoxetine, and 59% 
(30/51) to placebo.
DISCUSSION
The results of the EFFECTS trial show that fluoxetine 20 
mg daily for 6 months after acute stroke had no effect 
on functional outcome up to 1 year after stroke. Simi-
lar results have been found in the FOCUS (Fluoxetine 
or Control Under Supervision trial)5 (n=3124, United 
Kingdom), and AFFINITY (Assessment of Fluoxetine 
in Stroke Recovery)4 (n=1260, Australia, New Zealand 
and Vietnam) trials.
Although fluoxetine reduced depression by ≈4% 
(from 11% to 7%) at 6 months in EFFECTS, the pro-
portion of patients on an antidepressant was similar 
for the 2 groups at 12 months (9%). Depression is 
an episodic disorder for most, and not being on anti-
depressant right at the 12 months assessment does 
not exclude they did not take one between 6 and 11 
months; we cannot rule out that some patients were 
successfully treated already and drug not needed. Com-
pared with our 6-month follow-up, no clinical evaluation 
of depression symptoms was performed at 12 months. 
In a meta-analysis of observational studies, the pooled 
frequency of depression 6 to 12 months poststroke 
was 31% and 33%, respectively,22 >3× higher than the 
observed proportion in EFFECTS. One possible expla-
nation might be that EFFECTS included patients with 
relatively mild stroke. Another explanation might be that 
patients showing symptoms of depression before study 
start were not included.
Our finding of better reported memory and communi-
cation for patients in the placebo group compared with 
those allocated to the fluoxetine group is unexpected 
and not supported by the results in FOCUS and AFFIN-
ITY. We view this result as a chance finding due to ran-
dom error associated with multiple analyses.
Our study has several limitations. First, we did not 
routinely collect data on safety after 6 months, except 
death. Reassuringly, there was no difference between 
the groups in death, and we plan to follow the patients 
for at least 3 years via central registries in Sweden, 
Table 1. Modified Rankin Scale10 Score 6 and 12 Months After Randomization
modified Rankin 
Scale  









0 No symptoms 156 (21) 170 (23) 160 (22) 178 (25)
1 No clinically significant disability despite symptoms 216 (29) 199 (27) 224 (31) 201 (28)
2 Slightly disability: unable to do everything 94 (13) 106 (14) 75 (11) 88 (12)
3 Moderately disability: unable to live independently but can walk 168 (23) 164 (22) 158 (22) 141 (20)
4 Moderately disability and unable to walk without help from 
another person
46 (6) 48 (7) 35 (5) 42 (6)
5 Severe disability: unable to sit up 32 (4) 33 (4) 29 (4) 28 (4)
6 Dead 25 (3) 22 (3) 34 (5) 34 (5)
Data at 6 mo have previously been published.3 Data are n (%). Adjusted odds ratio at 6 mo: 0.94 (95% CI, 0.78–1.13). Common odds ratio at 6 mo: 0.97 (95% CI, 
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to collect data on depression, fractures and epilepsy. 
Second, we did not monitor the level and intensity of 
rehabilitation between 6 and 12 months. Third, our 
definition of depression as a patient on an antidepres-
sant drug is crude, probably underestimating the true 
occurrence, and it would have been better to evaluate 
depression face-to-face, as we did at 6 months. None-
theless, defining depression—not the least in the con-
text of brain damage, is difficult—which is reflected in 
the varied incidence in the literature.22
Our result is probably generalizable to high-income 
countries with a similar healthcare structure.
In conclusion, fluoxetine 20 mg once daily for six 
months after acute stroke had no effect on functional 
outcome at 12 months. Patients allocated fluoxetine 
scored worse on memory and communication on the 
Stroke Impact Scale compared with placebo, but this is 
likely to be due to chance. More precise estimates of 
any effects of fluoxetine will be available from our pro-
spective meta-analysis of individual patient data from the 
FOCUS, AFFINITY, and EFFECTS trials.23
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Table 2. Secondary Outcomes at 6 and 12 Months by Allocated Treatment Group
 
Fluoxetine (n=750) at 6 
months
Placebo (n=750) at 6 
months  
Fluoxetine (n=642) at 12 
months follow-up
Placebo (n=638) at 12 
months follow-up  
N* Median IQR N* Median IQR P value† N* Median IQR N* Median IQR P value†
Stroke Impact Scale version 3.014 domains
Strength 694 75 (50–94) 689 75 (50–94) 0.67 662 75 (50–94) 658 75 (50–94) 0.88
Hand ability 690 81 (50–100) 692 88 (50–100) 0.99 664 81 (56–100) 661 81 (50–100) 0.75
Mobility 696 89 (72–100) 698 89 (72–97) 1.00 665 89 (69–100) 662 89 (72–100) 0.84
Motor‡ 697 80 (60–93) 695 81 (58–94) 0.95 665 79 (60–94) 661 80 (58–94) 0.88
Daily Activities 697 88 (69–98) 697 88 (68–98) 0.72 667 90 (70–98) 662 90 (68–98) 0.97
Physical function§ 697 77 (56–90) 697 77 (56–91) 0.81 667 76 (57–91) 662 77 (55-–92) 0.98
Memory 696 89 (79–100) 698 93 (82–100) 0.0064 666 89 (75–100) 662 93 (82–100) 0.0021
Communication 695 96 (82–100) 697 92 (86–100) 0.83 664 93 (82–100) 661 96 (86–100) 0.024
Mood and  
emotional control
695 81 (67–92) 696 76 (64–89) 0.0002 665 78 (64–89) 658 78 (64–89) 0.63
Participation 690 66 (46–89) 682 69 (44–89) 0.55 663 69 (46–91) 656 71 (47–93) 0.79
Recovery (VAS) 695 70 (50–90) 695 70 (50–90) 0.79 666 75 (50–90) 662 80 (50–90) 0.58
Fatigue18 692 56 (44–69) 692 56 (44–69) 0.74 662 56 (44–75) 658 56 (44–75) 0.22
MHI-5 score15 697 76 (64–88) 695 72 (60–88) 0.0086 667 76 (60–88) 660 76 (60-88) 0.57









Data on Stroke Impact Scale at 6 mo have previously been published.3 Stroke Impact Scale v 3.014 is a patient-reported design to assess stroke outcome, where higher scores are 
better. Fatigue18 was measured with the vitality sub-scale of the SF-36 questionnaire. Higher scores indicate more energy, less fatigue. The EQ-5D-5 L has 5 dimensions: mobility; 
personal care; usual activities; pain/discomfort; and anxiety/depression. We calculated an EQ-5D index using the UK cross-walk value, where 1 indicates the best health imaginable, 
and 0 indicates the worst health imaginable. EQ-5D-5L20 indicates The 5-level EQ-5D version; MHI-515, mental health inventory-5; and VAS, Visual Analogue Scale.
*The number of patients with each of the secondary outcome scores. Data were only available for those who survived and who completed sufficient questions to derive a score.
†Mann-Whitney U test, between fluoxetine and placebo at 6 and 12 mo, respectively.
‡Mean of the strength, hand ability, and mobility domains.
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